Vipul Devas

436 total citations
7 papers, 189 citations indexed

About

Vipul Devas is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Orthopedics and Sports Medicine. According to data from OpenAlex, Vipul Devas has authored 7 papers receiving a total of 189 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Orthopedics and Sports Medicine. Recurrent topics in Vipul Devas's work include Bone health and treatments (2 papers), Gastric Cancer Management and Outcomes (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Vipul Devas is often cited by papers focused on Bone health and treatments (2 papers), Gastric Cancer Management and Outcomes (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Vipul Devas collaborates with scholars based in United States, Switzerland and Japan. Vipul Devas's co-authors include Daiva Masanauskaite, Larry Seidman, Alan Kivitz, William Koltun, Kathleen Beusterien, Ronald Emkey, Peyman Hadji, Patrice Fardellone, H. W. Minne and Angelo A. Licata and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Bone and Mineral Research.

In The Last Decade

Vipul Devas

5 papers receiving 178 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vipul Devas United States	3	144	137	31	24	23	7	189
Daiva Masanauskaite United States	9	546 3.8×	486 3.5×	175 5.6×	28 1.2×	24 1.0×	11	621
Polly A. Newcomb United States	5	16 0.1×	100 0.7×	42 1.4×	6 0.3×		5	196
Limei Ran China	6	23 0.2×	13 0.1×	34 1.1×	5 0.2×		8	95
Marisa Perdomo United States	8	16 0.1×	270 2.0×	6 0.2×	20 0.8×		22	310
Leena Martola Finland	6	28 0.2×	23 0.2×	3 0.1×	23 1.0×		14	110
Tiago Vasconcelos Fonseca Brazil	4	70 0.5×	33 0.2×	12 0.4×	1 0.0×		10	324
Ali Al Amri Saudi Arabia	3	7 0.0×	12 0.1×	8 0.3×	5 0.2×	12 0.5×	7	59
Shraddha Vyas United States	8	6 0.0×	39 0.3×	18 0.6×	22 0.9×		12	154
Rajesh Pasricha India	8	2 0.0×	59 0.4×	8 0.3×	17 0.7×	6 0.3×	31	154
Louise Nott Australia	6	4 0.0×	48 0.4×	17 0.5×	30 1.3×	1 0.0×	10	132

Countries citing papers authored by Vipul Devas

Since Specialization

Citations

This map shows the geographic impact of Vipul Devas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vipul Devas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vipul Devas more than expected).

Fields of papers citing papers by Vipul Devas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vipul Devas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vipul Devas. The network helps show where Vipul Devas may publish in the future.

Co-authorship network of co-authors of Vipul Devas

This figure shows the co-authorship network connecting the top 25 collaborators of Vipul Devas. A scholar is included among the top collaborators of Vipul Devas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vipul Devas. Vipul Devas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Awad, Mark M., Jonathan Spicer, Fedor V. Moiseyenko, et al.. (2026). Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis. Nature Cancer. 7(1). 169–181.

Deutsch, Julie S., Ashley Cimino‐Mathews, Elizabeth D. Thompson, et al.. (2025). Abstract CT097: Associations between percent residual viable tumor (%RVT) and efficacy with perioperative nivolumab (NIVO) for resectable NSCLC in CheckMate 77T. Cancer Research. 85(8_Supplement_2). CT097–CT097.

Provencio, Mariano, Mark M. Awad, Jonathan Spicer, et al.. (2024). Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study.. Journal of Clinical Oncology. 42(17_suppl). LBA8007–LBA8007. 9 indexed citations

Hadji, Peyman, H. W. Minne, Michael Pfeifer, et al.. (2008). Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Joint Bone Spine. 75(3). 303–310. 50 indexed citations

Cosman, Felicia, Michael R. McClung, Clifford J. Rosen, et al.. (2005). Rationale and design of the MOTION study (monthly oral therapy with ibandronate for osteoporosis intervention).. Journal of Bone and Mineral Research. 20. 2 indexed citations

Emkey, Ronald, William Koltun, Kathleen Beusterien, et al.. (2005). Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Current Medical Research and Opinion. 21(12). 1895–1903. 127 indexed citations

Cabrera, Javier, Vipul Devas, & Luisa Turrin Fernholz. (2005). Target estimation for the logistic regression model. Journal of Statistical Computation and Simulation. 75(2). 121–140. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact